This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Towle, M. J. Articles by Littlefield, B. A. Search for Related Content PubMed PubMed Citation Articles by Towle, M. J. Articles by Littlefield, B. A.

Inhibition of Urokinase by 4-substituted Benzo[b]thiophene-2-carboxamidines: An Important New Class of Selective Synthetic Urokinase Inhibitor

Sections of Biology [M. J. T., B. A. L.] and Chemistry [A. L., E. C. M., C. E. S., A. J. B.], Eisai Research Institute, Andover, Massachusetts 01810

Urokinase-type plasminogen activator (uPA) is an important mediator of cellular invasiveness. Specifically, cell surface receptor-bound uPA activates plasminogen to the potent general protease plasmin, which then degrades extracellular matrix or basement membrane either directly or via proteolytic activation of latent collagenases. Thus, cell surface uPA initiates an extracellular proteolytic cascade with which invasive cells eliminate barriers to movement. Since cellular invasiveness plays important roles in several disease states, including cancer metastasis and invasion, arthritis and inflammation, and diabetic retinal neovascularization, the development of synthetic uPA inhibitors is an attractive therapeutic goal. Here we show that 4-substituted benzo[b]thiophene-2-carboxamidines represent an important new class of potent and selective synthetic uPA inhibitor. Two compounds in this class, B428 and B623, inhibit human uPA in plasminogen-linked assays with median inhibition concentration (IC₅₀) values of 0.32 and 0.07 µM, respectively. This level of inhibition represents 20- and 100-fold increases in potency, respectively, relative to the 6–7 µM potencies reported for amiloride and 4-chlorophenylguanidine, the two most potent selective synthetic uPA inhibitors previously described. Importantly, both compounds show >300-fold selectivity for uPA relative to tissue-type plasminogen activator and >1000-fold selectivity relative to plasmin. Lineweaver-Burk analyses show uPA inhibition by B428 and B623 to be competitive in nature with inhibition constants (K₁) of 0.53 and 0.16 µM, respectively. Since it is cell surface uPA and not free or secreted uPA that is primarily responsible for cellular invasiveness, biologically effective uPA inhibitors must be capable of inhibiting cell surface uPA. B428 and B623 meet this criterion by inhibiting cell surface uPA on HT1080 human fibrosarcoma cells with IC₅₀ values of 0.54 and 0.20 µM, respectively. Moreover, degradation of [³H]fibronectin by HT1080 cells via cell surface uPA-mediated, plasminogen-dependent mechanisms is inhibited by B428 and B623, with IC₅₀ values of 1.5 and 0.39 µM, respectively. In summary, 4-substituted benzo[b]thiophene-2-carboxamidines such as B428 and B623 represent the most potent class of competitive synthetic uPA inhibitors currently known. Their ability to selectively inhibit both free and cell surface uPA as well as cell surface uPA-mediated cellular degradative functions suggests that this class of compounds may hold significant promise for further development as antiinvasiveness drugs.

¹ To whom requests for reprints should be addressed, at Section of Biology, Eisai Research Institute, 4 Corporate Drive, Andover, MA 01810.

Received 11/17/92. Accepted 2/25/93.

This article has been cited by other articles:

				B. Fingleton, R. Menon, K. J. Carter, P. D. Overstreet, D. L. Hachey, L. M. Matrisian, and J. O. McIntyre Proteinase Activity in Human and Murine Saliva as a Biomarker for Proteinase Inhibitor Efficacy Clin. Cancer Res., December 1, 2004; 10(23): 7865 - 7874. [Abstract] [Full Text] [PDF]

				T. Nishiuma, T. H. Sisson, N. Subbotina, and R. H. Simon Localization of Plasminogen Activator Activity within Normal and Injured Lungs by In Situ Zymography Am. J. Respir. Cell Mol. Biol., November 1, 2004; 31(5): 552 - 558. [Abstract] [Full Text] [PDF]

				K. HORINO, A. L. KINDEZELSKII, V. M. ELNER, B. A. HUGHES, and H. R. PETTY Tumor cell invasion of model 3-dimensional matrices: demonstration of migratory pathways, collagen disruption, and intercellular cooperation FASEB J, April 1, 2001; 15(6): 932 - 939. [Abstract] [Full Text] [PDF]

				S. Sperl, U. Jacob, N. Arroyo de Prada, J. Sturzebecher, O. G. Wilhelm, W. Bode, V. Magdolen, R. Huber, and L. Moroder (4-Aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase PNAS, May 9, 2000; 97(10): 5113 - 5118. [Abstract] [Full Text] [PDF]

				V. Nienaber, J. Wang, D. Davidson, and J. Henkin Re-engineering of Human Urokinase Provides a System for Structure-based Drug Design at High Resolution and Reveals a Novel Structural Subsite J. Biol. Chem., March 15, 2000; 275(10): 7239 - 7248. [Abstract] [Full Text] [PDF]

				C. P. Webb, C. D. Hose, S. Koochekpour, M. Jeffers, M. Oskarsson, E. Sausville, A. Monks, and G. F. Vande Woude The Geldanamycins Are Potent Inhibitors of the Hepatocyte Growth Factor/Scatter Factor-Met-Urokinase Plasminogen Activator-Plasmin Proteolytic Network Cancer Res., January 1, 2000; 60(2): 342 - 349. [Abstract] [Full Text]

				C.-I W. Q. Y. and Charles S. Craik and C. I. Wang Isolation of a High Affinity Inhibitor of Urokinase-type Plasminogen Activator by Phage Display of Ecotin J. Biol. Chem., May 19, 1995; 270(20): 12250 - 12256. [Abstract] [Full Text] [PDF]